Delving into the Latest Updates on Ipilimumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [17]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

MSI-H/dMMR Rectal CancerPD-L1 positive Non-Small Cell Lung CancerMetastatic hepatocellular carcinoma+ [266]

Inactive Indication

Acute bilineal leukemiaAcute Biphenotypic LeukemiaAcute lymphoblastic leukemia recurrent+ [153]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

National Cancer Institute

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

+ [17]

Inactive Organization

Checkmate Pharmaceuticals, Inc.

University of Southern California

Personal Genome Diagnostics, Inc.

+ [11]

License Organization

Nektar Therapeutics

Inspirna, Inc.

Nexoplex Bio, Inc.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (25 Mar 2011),

Melanoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival

Start Date01 Nov 2026

Sponsor / Collaborator

Centre Georges François Leclerc

NCT07689175

/ Not yet recruitingPhase 2IIT

Phase 2 Trial of Adaptive Dosing of Immune Checkpoint Inhibitors for Unresectable Child Pugh B Hepatocellular Carcinoma

The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

Start Date31 Oct 2026

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

[+1]

NCT07511036

/ Not yet recruitingPhase 2IIT

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.

Start Date01 Sep 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Ipilimumab

Login to view more data

100 Translational Medicine associated with Ipilimumab

Login to view more data

100 Patents (Medical) associated with Ipilimumab

Login to view more data

5,775

Literatures (Medical) associated with Ipilimumab

31 Dec 2026·CNS oncology

Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy

Article

Author: Ceccarelli, Corrado ; Pastina, Ilaria ; Del Roscio, Davide ; De Angelis, Filippo ; Viterbo, Antonella ; Pieraccini, Massimo ; Arezzini, Luca

CASE PRESENTATION:

We describe a 62-year-old man with disseminated melanoma (initially staged pT2aN0M0, AJCC stage IB, 8th edition AJCC) who developed multiple brain metastases with hemorrhagic transformation, pulmonary embolism, retrobulbar progression with eyeball herniation, and deep vein thrombosis (DVT). After cerebral edema improved with corticosteroid tapering and the patient became asymptomatic, he started combination immunotherapy with ipilimumab (3 mg/kg q3w × 4) and nivolumab (1 mg/kg q3w × 4). Despite initial benefit, progression led to radiotherapy for retrobulbar lesion and subsequent targeted therapy with encorafenib (450 mg daily) and binimetinib (45 mg twice daily). Shortly after, the patient developed symptomatic left-leg DVT extending to the femoral vein with segmental pulmonary embolism. Given the contraindication to full anticoagulation, mechanical thrombectomy with the Indigo Aspiration System was performed, followed by prophylactic LMWH at reduced therapeutic dose (enoxaparin 1 mg/kg once daily due to recent thrombectomy and hemorrhagic risk from bleeding brain metastases). During targeted therapy, the patient experienced partial regression of brain, liver, and peritoneal metastases, although intracranial hemorrhage recurred later.

CONCLUSIONS:

This case highlights the value of a multidisciplinary, tailored approach integrating immunotherapy, radiotherapy, targeted therapy, and mechanical thrombectomy with no DVT recurrence observed following thrombectomy at 6-month follow-up.

01 Dec 2026·JOURNAL OF BIOMOLECULAR NMR

A fast and efficient strategy for the NMR assignment of Fab methyl groups

Article

Author: Henot, Faustine ; Doyen, Camille ; Frances, Oriane ; Güntert, Peter ; Vibert, Béatrice ; Crublet, Elodie ; Favier, Adrien ; Dbira, Sarra ; Giraud, Arthur ; Imbert, Lionel ; Boisbouvier, Jérôme ; Clavier, Séverine

Owing to their high specificity and therapeutic effectiveness, monoclonal antibodies (mAbs) have rapidly become one of the leading classes of biologic drugs used to treat critical illnesses. The antigen-binding fragment (Fab) of mAbs plays a key role in the antigen recognition, so its structural characterization is essential, as even a slight change to its Higher Order Structure (HOS) can impact the antibody's potency. Recently, 2D methyl NMR has been introduced as a powerful method to assess both the structure and integrity of therapeutic Fab fragments. However, the identification of methyl group resonances in NMR spectra remains rare since Fabs are large heterodimers of ~ 50 kDa. Here, we present the methyl group assignment of an IgG1 Fab produced in a cell-free system with an optimal isotope labelling. We first assigned 99% of the alanine, isoleucine, leucine, methionine, and valine methyl groups of the therapeutic Fab targeting LAMP1 antigen. Building on this assignment, we propose a "divide and conquer" strategy that exploits sequence identities to rapidly assign methyl groups of other IgG1 Fabs. We demonstrate that the assignment of the Fab's constant region can easily be transferred from one IgG1 to another and that the variable part of a new Fab can be assigned using smaller uniformly ¹⁵N,¹³C-labelled constructs. We applied our strategy to ipilimumab's Fab and, using the assignment of ipilimumab's variable part and Fab anti-LAMP1's constant part, we could transfer the assignment of 89% of the methyl-containing amino acids to the entire ipilimumab Fab without having to produce deuterated samples. This assignment strategy can be generalised to any other IgG1 Fabs provided that their constant regions are identical and the strategy can be adapted to accommodate the expression levels of the different variable domains. This new method drastically facilitates the Fab assignment process, making it suitable for the pharmaceutical timeline.

01 Aug 2026·SEMINARS IN ONCOLOGY

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer

Article

Author: Guarin, Geneva ; Bhandari, Sambhawana ; Baral, Maun R ; Ranganathan, Prabha ; McEvoy, Colleen ; Morgensztern, Daniel

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can cause excessive immune activation, leading to severe adverse events, including intensive care unit (ICU) admission. Existing evidence on critical illness after ICI use is limited, largely single center, and focused on immune related adverse events. This study evaluates the risk of inpatient and ICU admissions after ICI initiation using two large national databases. We retrospectively analyzed MarketScan Commercial and Multi-state Medicaid Research Databases (2016-2022) to identify adults with solid organ malignancies treated with ICIs and determined if ICU admission was required within 90 days of ICI administration. The primary diagnosis for ICU admission was identified and categorized. Associations between cancer type, ICI type, and ICU admission were analyzed. About 33,040 patients received ICIs during the study period. About 48.9% were male and 51.1% female. Pembrolizumab was the most used (49.3%), followed by nivolumab (31.9%), and ipilimumab (9.4%). Lung cancer was the most common malignancy (40.8%), followed by genitourinary (16%), melanoma (13%), gastrointestinal (12%), and breast (10%). About 22.0% (n = 7,216) of patients were hospitalized, and 8.7% (n = 2,872) required ICU admission. Infection was the most frequent reason for ICU admission, followed by respiratory causes. The odds of being admitted to the ICU were higher with combination ICI (OR = 1.51, P < .001) compared to ICI monotherapy. In conclusion, among patients with solid organ malignancies, nearly 9% required ICU admission within 90 days of ICI initiation, most commonly for infectious causes. These findings highlight the need for heightened vigilance for critical illness in patients treated with ICIs.

1,007

News (Medical) associated with Ipilimumab

28 Jul 2026

·www.bioinvent.com

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and overcome resistance BI-1206 boosts αPD-1 antibody activity by protecting effector CD8+ T cells from macrophage-mediated depletion, a mechanism identified as limiting αPD-1 efficacy Findings reinforce the mechanistic rationale for BI-1206's ongoing Phase 2a evaluation with pembrolizumab in first-line NSCLC and uveal melanoma; initial data expected second half of 2026 Complementary Fc-engineered variant BI-1607 enhances αCTLA-4 antibody activity, including ipilimumab, by deepening intratumoral Treg depletion Lund, Sweden – July 28, 2026 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announce that preclinical proof‑of‑concept data supporting the mechanistic rationale for BI-1206 and BI-1607 in combination with immune checkpoint blockade have been published in the peer-reviewed Journal of Experimental & Clinical Cancer Research (JECCR). The publication, titled "Tailored FcγR Blockade Enhances Immune Checkpoint Therapy and Overcomes Resistance," identifies tailored FcγR blockade as a strategy to overcome resistance to PD-1-directed checkpoint therapy. BI-1206, an anti-FcγRIIB antibody with a wild-type Fc domain, was shown to enhance the activity of the approved αPD-1 antibodies nivolumab and pembrolizumab by protecting effector CD8+ T cells from macrophage-mediated depletion. These findings provide the mechanistic foundation for BioInvent's ongoing Phase 2a evaluation of BI-1206 in combination with pembrolizumab in first-line NSCLC and uveal melanoma, with initial data expected in the second half of 2026. In the same study, structurally distinct anti-FcγRIIB antibody variants, BI-1607 and its murine surrogate, engineered with an Fc-silenced Fc domain, were shown to enhance αCTLA-4 antibodies, including ipilimumab, through selective FcγRIIB blockade. The BI-1607 program is currently paused as BioInvent focuses resources on advancing its lead programs BI-1206 and BI-1808. "This work resolves a longstanding question in the field: whether and how FcγRs affect immune checkpoint blockade efficacy," said Björn Frendéus, Chief Scientific Officer of BioInvent and corresponding author of the study. "The answer depends on which immune cells express the checkpoint target. When a checkpoint target sits on suppressive regulatory T cells, as with CTLA-4, FcγR engagement helps antibodies deplete them, an effect BioInvent's Fc-silenced BI-1607 was designed to amplify. When the target sits on the effector CD8+ T cells that deliver anti-tumor activity, as with PD-1, FcγR engagement causes those cells to be cleared instead. Blocking all FcγRs with an Fc-competent antibody like BI-1206 protects those CD8+ T cells and preserves αPD-1 efficacy. These findings provide the mechanistic foundation for BI-1206, our lead FcγRIIB-blocking antibody, and directly support the ongoing Phase 2a evaluation of BI-1206 in combination with pembrolizumab in first-line NSCLC and uveal melanoma." "Despite the transformative impact of checkpoint inhibitors, most patients still fail to benefit long-term from these therapies," said Mark S. Cragg, Professor of Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton and co-senior author of the study. "The mechanistic insights described in this paper give us a clear path to designing next-generation antibody combinations that address the underlying biology limiting current immunotherapy responses. This has been another highly productive collaboration between the Antibody and Vaccine Group at Southampton and BioInvent, and we look forward to seeing these principles translate into meaningful clinical benefit." Publication overview: Mechanistic basis for enhancing PD-1 and CTLA-4 checkpoint therapyImmune checkpoint inhibitors have transformed cancer treatment, yet most patients either do not respond or develop resistance during therapy. Understanding and overcoming that resistance is one of the field's most pressing challenges. Further limiting patient benefit, CTLA-4 checkpoint therapy is often dose-limited by toxicity. Fc gamma receptors (FcγRs) regulate therapeutic antibody activity by engaging immune effector cells. Prior work established that different checkpoint antibodies have opposing FcγR requirements: αPD-1 antibodies can be undermined by FcγR-dependent depletion of the very effector CD8+ T cells they are designed to reactivate, whereas αCTLA-4 antibodies rely on FcγR engagement to deplete tumor-infiltrating regulatory T cells. The JECCR study reconciles these opposing requirements and identifies tailored FcγR blockade with BI-1206 as a strategy to overcome αPD-1 resistance and with BI-1607 to enhance αCTLA-4 efficacy in a tumor-selective manner, potentially improving tolerability. About the StudyThe study was conducted by researchers at BioInvent International and the University of Southampton's Antibody and Vaccine Group, School of Cancer Sciences. Stephen A. Beers and Mark S. Cragg (University of Southampton) and Ingrid Teige and Björn Frendéus (BioInvent) share senior authorship; Frendéus is corresponding author. The processed and raw single-cell RNA sequencing data have been deposited in the NCBI Gene Expression Omnibus under accession number GSE335831. About BI-1206FcγRIIB is an inhibitory Fc gamma receptor often upregulated in the tumor microenvironment. Alongside activating Fc gamma receptors, FcγRIIB expressed on immune effector cells can limit the efficacy of PD-1-directed checkpoint therapy. BI-1206 is a human anti-FcγRIIB monoclonal antibody with a wild‑type Fc domain, designed to block FcγRs on tumor-associated macrophages, thereby preventing macrophage-mediated depletion of PD-1-coated CD8+ T cells and preserving αPD-1 antitumor activity. A Phase 2a study of BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) is ongoing in treatment-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma, with initial data expected in the second half of 2026 (NCT04219254). BI-1206 is also being evaluated in a separate Phase 2a triple combination with rituximab and Calquence® (acalabrutinib) in relapsed/refractory non-Hodgkin's lymphoma, where the antibody addresses a distinct resistance mechanism relevant to CD20-directed therapy (NCT03571568). About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available on the Company’s website. For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: cecilia.hofvander@bioinvent.comBioInvent International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 50www.bioinvent.com The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

ImmunotherapyPhase 2

28 Jul 2026

·www.biospace.com

FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm

iStock , useng The FDA’s rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy. The FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of an oncolytic immunotherapy “not interpretable,” setting up what should be a challenging advisory committee meeting for the biotech this week. The drug, vusolimogene oderparepvec, or RP1, has been rejected by the FDA twice . The agency accepted another resubmission in June and committed to rendering a third verdict by August 2—but also announced a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) to discuss the therapy. Two days ahead of that Thursday meeting , FDA briefing documents show that the agency still has significant concerns about the data package that Replimune has offered to support RP1’s accelerated approval in combination with Bristol Myers Squibb’s PD-1 inhibitor Opdivo for adults with unresectable advanced cutaneous melanoma who experience disease progression after a PD-1-blocking antibody-based therapy. ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); The response assessment used in the Phase 1/2 IGNYTE study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results,” the FDA reviewers said. Moreover, the agency determined that the objective response data from the single-arm trial “are not of sufficient magnitude to overcome concerns” about the drug’s efficacy. Without a reliable historical control, the FDA stated “it cannot be determined whether RP1 contributes to any observed effect” when combined with Opdivo. “The overall survival analysis from the single-arm IGNYTE study is not interpretable,” the FDA wrote. Replimune was down as much as 20% to $6.98 in premarket trading Tuesday. Replimune argued that experts have determined a randomized trial to be unethical in this population. “It is not feasible or ethical to randomize this patient population to a comparator arm of anti-PD-1 monotherapy that offered no hope for response, therefore a study comparing RP1 in combination with nivolumab, to nivolumab monotherapy in patients whose disease progressed while on nivolumab or other anti-PD-1 was not conducted,” the company wrote in its own briefing document . Replimune also addressed the FDA’s questions regarding historical data. When IGNYTE was performed, there were no treatments available for patients who had progressed after anti-PD-1 treatment, the company explained. And there is no evidence that continuing on an anti-PD-1 therapy poses any benefit to patients. “Consequently, there is very little literature evaluating this specific scenario, as continuing a therapy that has definitively failed would generally not be considered appropriate clinical practice,” Replimune wrote, adding that the IGNYTE study had strict criteria to ensure patients were “truly anti-PD-1 resistant.” Replimune also pointed out that the FDA has previously granted approval based on a single-arm study for melanoma patients. Iovance Biotherapeutics most recently received approval in 2024 for Amtagvi in this scenario. Merck’s Keytruda and Opdivo also got FDA nods for unresectable or metastatic melanoma following that of BMS’s Yervoy with single arm trials. With Replimune, however, the FDA has been consistent in its disagreement with this study design. In its first complete response letter in July 2025, the FDA said it “did not consider IGNYTE an “adequate and well-controlled clinical investigation,” a ccording to Replimune at the time. In a second CRL in April, trial design remained the sticking point for the regulator, which wrote that it “would not recommend” seeking approval based on results from a single-arm study. Complete response letters Replimune’s advanced melanoma drug rebuffed by FDA for second time The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used to support the application for RP1. April 10, 2026 · 2 min read · Heather McKenzie Read more On Thursday, the CTGTAC will vote on just one question: Are the efficacy results from IGNYTE evaluable and clinically meaningful? Replimune’s turn before the CTGTAC will be the committee’s second event this week. On Monday, the FDA similarly released adcomm documents for Capricor’s Duchenne muscular dystrophy cell therapy deramiocel. The agency disagrees with the company’s claim that a Phase 3 trial submitted to support approval was successful. That hearing will take place Wednesday. The meetings follow a nine-month drought of adcomms at the FDA under the Trump administration. After a leadership shakeup, the agency appears to be recommitting to these public meetings. FDA FDA has recommitted to adcomms—but to what end? The FDA will hold advisory committee meetings this week for previously rejected investigational therapies from Replimune and Capricor Therapeutics. Some industry leaders were surprised the meetings were called at all, while many have questioned the rationale behind them and other adcomms on deck. July 27, 2026 · 5 min read · Michael Gibney Read more

Phase 3Cell TherapyAccelerated ApprovalDrug Approval

23 Jul 2026

·www.fiercebiotech.com

Scancell to go public after winning reverse merger bid for troubled Neuphoria

Scancell Holdings and Neuphoria Therapeutics have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders after the biotech ended its social anxiety program last year. London-based Scancell will acquire Neuphoria in an all-stock transaction accompanied by $89 million in debt and equity financing, according to a Thursday release . Scancell proposed the merger last month to raise its profile with U.S. investors. The financing will be used to support a global phase 3 trial for Scancell’s lead asset, iSCIB1+, an immunotherapy for advanced melanoma that has received fast-track designation from the FDA. Scancell, which plans to list under the ticker “SCLT,” said it has sufficient funding to propel the company through 2029. The latest data from the biotech's phase 2 study showed 77% progression-free survival at 22 months when iSCIB1+ was combined with Bristol Myers Squibb’s immunotherapies Yervoy and Opdivo. More data from the study is expected later this year. “We believe the compelling data from our phase 2 Scope study demonstrating benefit to patients across multiple clinical endpoints warrants pressing forward to evaluate the product in a registrational randomized study,” Scancell’s CEO Phil L’Huillier, Ph.D., said in the release. “We strongly believe this transaction creates meaningful near- and long-term value for shareholders of both companies.” Neuphoria underwent a strategic review after soclenicant, an α7 nicotinic receptor negative allosteric modulator, failed to hit its primary endpoint in a phase 3 trial for patients with social anxiety disorder last October. The results caused Neuphoria’s stock to shed a third of its pre-readout value and led the biotech to end the program . This summer brought more bad news for Neuphoria, as Merck & Co. ended the phase 2 study of a potential Alzheimer’s disease medicine that the two companies had partnered to develop. The asset, MK-1167, is a modulator of the alpha-7 nicotinic acetylcholine receptor and was being assessed for its ability to improve Alzheimer’s dementia symptoms when paired with a standard acetylcholinesterase inhibitor. Still, Neuphoria has had its fair share of suitors. The biotech announced back in December 2025 that it had received “substantial reciprocal interest” from several interested parties, including Puerto Rico-based Lynx1 Master Fund , a hedge fund manager that was already a Neuphoria investor. Scancell then put in its own bid last month. “We believe this transaction offers Neuphoria stockholders a compelling opportunity to participate in the future value creation of Scancell’s differentiated oncology pipeline,” said Neuphoria Chairman Alan Fisher. The $89 million in financing comprises a $39.1 million private placement, a $12 million U.K. placing, a retail offer of $3 million, $25 million in debt financing from BlackRock and at least $10 million from Neuphoria’s cash balances. Existing Scancell shareholders will own 85.5% of the combined company, with existing Neuphoria shareholders owning the remaining 14.5%.

100 Deals associated with Ipilimumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
MSI-H/dMMR Rectal Cancer	Japan	Bristol-Myers Squibb KK	25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer	China	Bristol-Myers Squibb Pharma EEIG	22 Jul 2025
Metastatic hepatocellular carcinoma	Australia	Bristol-Myers Squibb Australia Pty Ltd.	27 Jun 2025
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Mismatch repair-deficient Colonic Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma	United States	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	Japan	Bristol-Myers Squibb KK	26 May 2022
Hepatocellular Carcinoma	United States	Bristol Myers Squibb Co.	10 Mar 2020
Melanoma, Cutaneous Malignant	United States	Bristol Myers Squibb Co.	10 Jul 2018
Colorectal Cancer	United States	Bristol Myers Squibb Co.	16 Apr 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	South Korea	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Taiwan Province	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Non-small cell lung cancer stage III	Phase 3	Netherlands	Bristol Myers Squibb Co.	16 Dec 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	08 Oct 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04039607 (CheckMate 9DW, ESMO_GI2026 \| ESMO_GCC2026)	Phase 3	Unresectable Hepatocellular Carcinoma First line	208	Nivolumab (NIVO) + ipilimumab (IPI)	krfymanndb(dzycifanud) = fruthghhgh psxzndtqwm (muyahuyhos, 4.9 - NR) View more	Positive	02 Jul 2026
				Lenvatinib (LEN) or Sorafenib (SOR)	krfymanndb(hkhvigazpy) = kmcswyfkyx fkegazloaz (hpcapgsdkn, 13.9 - 24.7) View more
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	PD-L1 positive Esophageal Squamous Cell Carcinoma	26	Nivolumab + ipilimumab	aieelwwskn(nvqvifelty) = ruzboxdurs djupkjefoc (romkyysdsd ) View more	Negative	02 Jul 2026
NCT03682276 (PRIME-HCC, CTgov)	Phase 1/2	Hepatocellular Carcinoma	33	Ipilimumab+Nivolumab	nuusqgutsl = hjfqpgfftb eybyxmuhxh (thxuazezec, bdmxwmqrpp - idnqwntvnb) View more	-	29 Jun 2026
NCT03958383 (CTgov)	Phase 1/2	Melanoma	8	hu14.18-IL2 fusion protein (Phase IA)	lrpbvnsrjj = ezybqsgctf xfnzaukhrc (vepyaeozgm, glyabliyzu - viekemkwva) View more	-	03 Jun 2026
				hu14.18-IL2 (Phase IB)	lrpbvnsrjj = vatpggonuh xfnzaukhrc (vepyaeozgm, wbhobvcpot - crakzkzoiq) View more
NCT05665348 (PRODIGE 81-FFCD 2101-TRIPLET HCC, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 2/3	Advanced Hepatocellular Carcinoma First line	226	Atezolizumab + Bevacizumab + Ipilimumab	tlbowmgnaj(ldsmuqaipa) = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure kzkcvatvwt (kpursjfjwr ) View more	Negative	01 Jun 2026
				Atezolizumab + Bevacizumab
ASCO2026	Not Applicable	Melanoma Neoadjuvant	130	Pembrolizumab	anjlusxfbb(nytfozxqpg) = yllnquwjzy irkjhcvkvv (rzfdiajhqb ) View more	Positive	29 May 2026
				Nivolumab + Ipilimumab	anjlusxfbb(nytfozxqpg) = xcmvysowoj irkjhcvkvv (rzfdiajhqb ) View more
ASCO2026	Not Applicable	Renal Cell Carcinoma First line	2,760	Immune checkpoint inhibitors (BMI ≥25 kg/m2)	nqoptvsbwx(tviqyxwuim) = Rates of emergency department visits, hospitalizations, and ICU admissions were similar between groups at both 1 and 3 years. hgrfwoybos (qmylfebtrx ) View more	Positive	29 May 2026
				Immune checkpoint inhibitors (BMI 18.5- < 25 kg/m2)
NCT06712927 (RELATIVITY-048, ASCO2026)	Phase 2	Melanoma	60	Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	ebuiuzjylz(okzgtwqavt) = mxaihjusef qupclhimqz (azyalhqnaa ) View more	Positive	29 May 2026
				Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	ebuiuzjylz(okzgtwqavt) = qcrciqifwa qupclhimqz (azyalhqnaa )
CheckMate 9DW (ASCO2026)	Phase 2	Unresectable Hepatocellular Carcinoma First line	1,160	Ipilimumab/Nivolumab	drfrpsszkc(kalobeoefb) = qkldeqkdzy sqzhjepbgn (egimpsxflf ) View more	Positive	29 May 2026
				Durvalumab/Tremelimumab	drfrpsszkc(kalobeoefb) = kvetbuhpea sqzhjepbgn (egimpsxflf ) View more
NCT06295159 (ASCO2026)	Phase 2	Melanoma Neoadjuvant	20	Ipilimumab-Nivolumab-Relatlimab (INR)	nusqcqsfyb(kayoytizey) = rqzfgitmar zjfgtibhov (frxycowrvf, 44.40 - 85.84) View more	Positive	29 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Ipilimumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation